ArticleBioactive materials2024
Biodegradable WE43 Mg alloy/hydroxyapatite interpenetrating phase composites with reduced hydrogen evolution.
Article in Bioactive materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Current Options and Future Perspectives for Conversion Coatings on Biodegradable Magnesium Alloys to Control the Biodegradation Rate and Biological Features.Biomimetics (Basel, Switzerland) · 2026Review
- Microstructure and corrosion resistance of AZ91- Hydroxyapatite composites processed via deformation-driven metallurgy.Journal of materials science. Materials in medicine · 2025Article
- Integrating Additive and Traditional Manufacturing for Multiscale Bone Tissue Engineering Scaffolds.Journal of functional biomaterials · 2025Review
- Interpenetrating Composites: A Nomenclature Dilemma.Materials (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biodegradable magnesium implants offer a solution for bone repair without the need for implant removal. However, concerns persist regarding peri-implant gas accumulation, which has limited their widespread clinical acceptance. Consequently, there is a need to minimise the mass of magnesium to reduce the total volume of gas generated around the implants. Incorporating porosity is a direct approach to reducing the mass of the implants, but it also decreases the strength and degradation resistance. This study demonstrates that the infiltration of a calcium phosphate cement into an additively manufactured WE43 Mg alloy scaffold with 75 % porosity, followed by hydrothermal treatment, yields biodegradable magnesium/hydroxyapatite interpenetrating phase composites that generate an order of magnitude less hydrogen gas during degradation than WE43 scaffolds. The enhanced degradation resistance results from magnesium passivation, allowing osteoblast proliferation in indirect contact with composites. Additionally, the composites exhibit a compressive strength 1.8 times greater than that of the scaffolds, falling within the upper range of the compressive strength of cancellous bone. These results emphasise the potential of the new biodegradable interpenetrating phase composites for the fabrication of temporary osteosynthesis devices. Optimizing cement hardening and magnesium passivation during hydrothermal processing is crucial for achieving both high compressive strength and low degradation rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.